Targeted Delivery of a Short Antimicrobial Peptide (CM11) Against Helicobacter Pylori Gastric Infection Using Concanavalin A-coated Chitosan Nanoparticles

Overview

Journal J Mater Sci Mater Med

Publisher Springer

Specialty Biomedical Engineering

Date 2023 Aug 31

PMID 37650975

Authors

Mehrdad Moosazadeh Moghaddam

Shahin Bolouri

Reza Golmohammadi

Mahdi Fasihi-Ramandi

Mohammad Heiat

Reza Mirnejad

Affiliations

Soon will be listed here.

Abstract

Helicobacter pylori is the cause of most cases of stomach ulcers and also causes some digestive cancers. The emergence and spread of antibiotic-resistant strains of H. pylori is one of the most important challenges in the treatment of its infections. The present study aims to develop a concanavalin A (ConA) coated chitosan (CS) nanocarrier-based drug delivery for the targeted release of peptides to the site of H. pylori infection. Accordingly, chitosan was used as an encapsulating agent for CM11 peptide delivery by applying ionotropic gelation method. Con-A was used for coating CS nanoparticles to target H. pylori. The CS NPs and ConA-CS NPs were characterized by FTIR, dynamic light scattering (DLS), and scanning electron microscopy (SEM). The MIC of CM11-loaded ConA-CS NPs against H. pylori SS1 strain was analyzed in vitro. In order to evaluate the treatment efficiency in vivo, a gastric infection model of H. pylori SS1 strain was established in mice and histopathological studies and IL-1β cytokine assay were performed. Based on the results, the size frequency for CS NPs and ConA-CS NPs was about 200 and 350 nm, respectively. The prepared CM11-loaded ConA-CS NPs exhibited antibacterial activity against H. pylori SS1 strain with a concentration of 32 µg/ml. The highest healing process was observed in synthesized CM11-loaded ConA-CS NPs treatments and a significant decrease in IL-1β was observed. Our findings highlight the potential of chitosan nanoparticles as a drug delivery vehicle in the treatment of gastric infection model of H. pylori SS1 strain.

Citing Articles

and gastric cancer: current insights and nanoparticle-based interventions.

Shah S, Mumtaz M, Sharif S, Mustafa I, Nayila I RSC Adv. 2025; 15(7):5558-5570.

PMID: 39967885 PMC: 11834156. DOI: 10.1039/d4ra07886a.

Conjugated therapeutic proteins as a treatment for bacteria which trigger cancer development.

Halawa M, Newman P, Aderibigbe T, Carabetta V iScience. 2024; 27(10):111029.

PMID: 39635133 PMC: 11615139. DOI: 10.1016/j.isci.2024.111029.

References

Wang Y, Gildersleeve J, Basu A, Zimmt M . Photo- and biophysical studies of lectin-conjugated fluorescent nanoparticles: reduced sensitivity in high density assays. J Phys Chem B. 2010; 114(45):14487-94. PMC: 2980569. DOI: 10.1021/jp101854m. View

Ebadi Zahmatkesh M, Jahanbakhsh M, Hoseini N, Shegefti S, Peymani A, Dabin H . Effects of Exosomes Derived From Outer Membrane Vesicle-Infected Hepatocytes on Hepatic Stellate Cell Activation and Liver Fibrosis Induction. Front Cell Infect Microbiol. 2022; 12:857570. PMC: 9271900. DOI: 10.3389/fcimb.2022.857570. View

Mohammadi M, Attar A, Mohammadbeigi M, Peymani A, Bolori S, Fardsanei F . The possible role of Helicobacter pylori in liver diseases. Arch Microbiol. 2023; 205(8):281. DOI: 10.1007/s00203-023-03602-z. View

Locke A, Cummins B, Abraham A, Cote G . PEGylation of concanavalin A to improve its stability for an in vivo glucose sensing assay. Anal Chem. 2014; 86(18):9091-7. PMC: 4165460. DOI: 10.1021/ac501791u. View

Mancuso G, Midiri A, Gerace E, Biondo C . Bacterial Antibiotic Resistance: The Most Critical Pathogens. Pathogens. 2021; 10(10). PMC: 8541462. DOI: 10.3390/pathogens10101310. View

Rima M, Rima M, Fajloun Z, Sabatier J, Bechinger B, Naas T . Antimicrobial Peptides: A Potent Alternative to Antibiotics. Antibiotics (Basel). 2021; 10(9). PMC: 8466391. DOI: 10.3390/antibiotics10091095. View

Garg U, Chauhan S, Nagaich U, Jain N . Current Advances in Chitosan Nanoparticles Based Drug Delivery and Targeting. Adv Pharm Bull. 2019; 9(2):195-204. PMC: 6664124. DOI: 10.15171/apb.2019.023. View

Mikusova V, Mikus P . Advances in Chitosan-Based Nanoparticles for Drug Delivery. Int J Mol Sci. 2021; 22(17). PMC: 8431817. DOI: 10.3390/ijms22179652. View

Shih C, Shie C, Hsu P . Update on the first-line treatment of infection in areas with high and low clarithromycin resistances. Therap Adv Gastroenterol. 2022; 15:17562848221138168. PMC: 9706057. DOI: 10.1177/17562848221138168. View

10.

Neshani A, Zare H, Akbari Eidgahi M, Hooshyar Chichaklu A, Movaqar A, Ghazvini K . Review of antimicrobial peptides with anti-Helicobacter pylori activity. Helicobacter. 2018; 24(1):e12555. DOI: 10.1111/hel.12555. View

11.

Zhao D, Yu S, Sun B, Gao S, Guo S, Zhao K . Biomedical Applications of Chitosan and Its Derivative Nanoparticles. Polymers (Basel). 2019; 10(4). PMC: 6415442. DOI: 10.3390/polym10040462. View

12.

Kurczewska J . Chitosan-Based Nanoparticles with Optimized Parameters for Targeted Delivery of a Specific Anticancer Drug-A Comprehensive Review. Pharmaceutics. 2023; 15(2). PMC: 9961640. DOI: 10.3390/pharmaceutics15020503. View

13.

Angsantikul P, Thamphiwatana S, Zhang Q, Spiekermann K, Zhuang J, Fang R . Coating nanoparticles with gastric epithelial cell membrane for targeted antibiotic delivery against infection. Adv Ther (Weinh). 2018; 1(2). PMC: 6176867. DOI: 10.1002/adtp.201800016. View

14.

Larsson D, Flach C . Antibiotic resistance in the environment. Nat Rev Microbiol. 2021; 20(5):257-269. PMC: 8567979. DOI: 10.1038/s41579-021-00649-x. View

15.

Herdiana Y, Wathoni N, Shamsuddin S, Muchtaridi M . Drug release study of the chitosan-based nanoparticles. Heliyon. 2022; 8(1):e08674. PMC: 8741465. DOI: 10.1016/j.heliyon.2021.e08674. View

16.

Jain S, Jangdey M . Lectin conjugated gastroretentive multiparticulate delivery system of clarithromycin for the effective treatment of Helicobacter pylori. Mol Pharm. 2008; 6(1):295-304. DOI: 10.1021/mp800193n. View

17.

Amani J, Barjini K, Moghaddam M, Asadi A . In vitro synergistic effect of the CM11 antimicrobial peptide in combination with common antibiotics against clinical isolates of six species of multidrug-resistant pathogenic bacteria. Protein Pept Lett. 2015; 22(10):940-51. DOI: 10.2174/0929866522666150728115439. View

18.

Savoldi A, Carrara E, Graham D, Conti M, Tacconelli E . Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology. 2018; 155(5):1372-1382.e17. PMC: 6905086. DOI: 10.1053/j.gastro.2018.07.007. View

19.

Sukri A, Lopes B, Hanafiah A . The Emergence of Multidrug-Resistant in Southeast Asia: A Systematic Review on the Trends and Intervention Strategies Using Antimicrobial Peptides. Antibiotics (Basel). 2021; 10(9). PMC: 8465560. DOI: 10.3390/antibiotics10091061. View

20.

Patra J, Das G, Fraceto L, Campos E, Del Pilar Rodriguez-Torres M, Acosta-Torres L . Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018; 16(1):71. PMC: 6145203. DOI: 10.1186/s12951-018-0392-8. View